CAMP4 Therapeutics Corporation (CAMP) Revenue History
Annual and quarterly revenue from 2013 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2022)
CAMP's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
By Geography
CAMP Revenue Analysis (2013–2024)
As of March 1, 2026, CAMP4 Therapeutics Corporation (CAMP) generated trailing twelve-month (TTM) revenue of $3.8 million. The most recent quarter (Q3 2025) recorded $795,000 in revenue, down 46.9% sequentially.
Looking at the longer-term picture, CAMP's 5-year compound annual growth rate (CAGR) stands at -71.8%, indicating revenue contraction over this period. The company achieved its highest annual revenue of $366.1 million in 2019.
Revenue diversification analysis shows CAMP's business is primarily driven by Product (64%), and Application Subscriptions And Other Services (36%). With over half of revenue concentrated in Product, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including ALNY (+65.2% YoY), IONS (+33.8% YoY), and ARWR (+4081.8% YoY). Compare CAMP vs ALNY →
Peer Comparison
Compare CAMP's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CAMPCurrent | $4M | - | -71.8% | -8142.3% | |
| ALNY | $3.7B | +65.2% | +49.8% | 13.5% | |
| IONS | $944M | +33.8% | +5.3% | -40.5% | |
| ARWR | $829M | +4081.8% | +56.6% | 11.9% | |
| CRSP | $4M | -81.7% | +37.3% | -18933.6% | |
| BEAM | $140M | +120.0% | +466.3% | -274.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $652K | +86.3% | $652K | 100.0% | $-53,088,000 | -8142.3% |
| 2023 | $350K | - | $350K | 100.0% | $-51,879,000 | -14822.6% |
| 2022 | $0 | -100.0% | $0 | - | $-45,001,000 | - |
| 2021 | $295.8M | -4.1% | $121.9M | 41.2% | $-15,313,000 | -5.2% |
| 2020 | $308.6M | -15.7% | $122.4M | 39.7% | $-3,869,000 | -1.3% |
| 2019 | $366.1M | +0.6% | $143.3M | 39.1% | $-16,770,000 | -4.6% |
| 2018 | $363.8M | -0.6% | $147.8M | 40.6% | $19.7M | 5.4% |
| 2017 | $365.9M | +4.2% | $150.9M | 41.2% | $8.0M | 2.2% |
| 2016 | $351.1M | +25.1% | $143.4M | 40.8% | $1.3M | 0.4% |
| 2015 | $280.7M | +12.0% | $103.0M | 36.7% | $28.1M | 10.0% |
See CAMP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CAMP Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare CAMP vs AGIO
See how CAMP stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is CAMP's revenue growth accelerating or slowing?
CAMP TTM revenue: $4M. YoY growth: N/A. 5-year CAGR: -71.8%.
What is CAMP's long-term revenue growth rate?
CAMP4 Therapeutics Corporation's 5-year revenue CAGR of -71.8% reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is CAMP's revenue distributed by segment?
CAMP reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2013-2024 are available for download. Segment mix reveals concentration and diversification trends.